August 18, 2025
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology. Trends Endocrinol Metab. 2025.
SGLT-2 inhibitors and GLP-1 receptor agonists, new medications that reduce the risk of heart disease in people with and without type 2 diabetes, may have a role to play in mitigating cardiovascular risk in type 1 diabetes.
